Intratumoral immune activation with TLR4 agonist synergizes with effector T cells to eradicate established murine tumors
Albershardt et al.
June 2020
Authors and Affiliates
Tina C Albershardt 1, Jardin Leleux 1, Andrea J Parsons 1, Jordan E Krull 1, Peter Berglund 1, Jan Ter Meulen 1; 1 Immune Design, a wholly-owned subsidiary of Merck & Co., Inc, Kenilworth, NJ USA.
